PDUFA
This article was originally published in The Tan Sheet
Executive Summary
Authority to waive or reduce prescription drug user fees redelegated to the director and associate director for policy at CDER. A final rule published Nov. 3 revokes authority previously delegated to the Chief Mediator and Ombudsman/User Fee Waiver Officer, the Deputy Chief Mediator and Ombudsman, and the Deputy User Fee Waiver Officer, except for reconsideration requests of user fee decisions made prior to July 1
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning